Jeffrey W. Albers - 07 Aug 2026 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Reporting relationship: Director
Issuer ticker: SYRE
Reported as of: 07 Aug 2026
Net transaction value: -$2,404,190
SEC form: 4
Accepted by SEC: 10 Aug 2026, 21:31:51 UTC
Prior SEC filing: 25 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Heidy King-Jones, as Attorney-in-Fact

Key filing fact

Jeffrey W. Albers filed Form 4 for Spyre Therapeutics, Inc. (SYRE) on 10 Aug 2026.

Key facts

This page summarizes Jeffrey W. Albers's Form 4 filing for Spyre Therapeutics, Inc. (SYRE).
5 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 10 Aug 2026, 21:31.

Change

Previous filing in this sequence was filed on 25 Jun 2026.
Current net transaction value: -$2,404,190.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001638474 Primary reporting owner

Albers Jeffrey W.

Relationship: Director
Address: 221 CRESCENT STREET, BUILDING 23,, SUITE 105, WALTHAM
Signature: /s/ Heidy King-Jones, as Attorney-in-Fact
Signature date: 10 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SYRE transaction

Common Stock

Options Exercise

Transaction value
Shares: +5,000
Change %
Price: $10.39^*
Shares after: 5,000
Date: 07 Aug 2026
Ownership: Direct
Footnotes: F1

SYRE transaction

Common Stock

Sale

Transaction value: $522,350
Shares: -5,000
Change %: -100%
Price: $104.47
Shares after: 0
Date: 07 Aug 2026
Ownership: Direct
Footnotes: F1, F2

SYRE transaction

Common Stock

Sale

Transaction value: $835,040
Shares: -8,000
Change %: -29%
Price: $104.38
Shares after: 19,360
Date: 07 Aug 2026
Ownership: By Sessions LLC
Footnotes: F1, F3

SYRE transaction

Common Stock

Sale

Transaction value: $1,046,800
Shares: -10,000
Change %: -52%
Price: $104.68
Shares after: 9,360
Date: 07 Aug 2026
Ownership: By Sessions LLC
Footnotes: F1, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SYRE transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -5,000
Change %: -10%
Price: $0.000000^*
Shares after: 45,000
Date: 07 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,000
Exercise price: $10.39
Footnotes: F1, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.

Footnote F2

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.59 to $105.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F3

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.52 to $105.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F4

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.60 to $106.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F5

This option represents a right to purchase 50,000 shares of the Issuer's common stock, which vest and become exercisable in 36 equal monthly installments beginning on November 22, 2023 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.